Manufacturer: Bioamino Labs
Pharmaceutical name: Semaglutide
Pack: 1 vial (2 mg)
Semaglutide is a powerful weekly GLP-1 receptor agonist that leads to notable reductions in HbA1c levels, body weight, and systolic blood pressure. However, its use is linked to a higher occurrence of gastrointestinal side effects. Further evaluation of its effects on pancreatitis and retinopathy is needed through post-marketing safety studies.
Semaglutide is categorized under glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which replicate the action of the GLP-1 hormone released by the intestine after food intake.
One of the functions of GLP-1 is to stimulate the pancreas to secrete more insulin, thus lowering blood sugar (glucose) levels. This is why Semaglutide has been utilized for over 15 years to manage Type 2 diabetes.
Moreover, elevated levels of GLP-1 also affect brain regions that control appetite and convey feelings of satiety. When combined with a balanced diet and regular exercise, it can result in substantial weight loss — along with a decreased risk of cancer, diabetes, and cardiovascular diseases — for individuals who are overweight or obese.
The side effects associated with semaglutide are generally mild, especially when contrasted with the health risks tied to being overweight and obese.
Individuals using semaglutide for weight reduction might notice:
Dizziness
Fatigue
Gastrointestinal symptoms, including diarrhea, constipation, and gas
Headache
Stomach-related issues, encompassing nausea, vomiting, discomfort, or bloating
Gastrointestinal problems are the most frequent concern for new users of semaglutide. However, starting with a lower dose and gradually increasing it might help mitigate these side effects.